Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of prognostic factors and outcomes in primary versus secondary myeloid sarcoma.

Human pathology·2026
Same author

Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia.

Blood neoplasia·2026
Same author

Hematolymphoid neoplasms involving the breast: A single institution clinicopathologic study of 59 patients.

Annals of hematology·2026
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026
Same author

Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Leukemia & lymphoma·2026
Same author

Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies.

American journal of hematology·2026
Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Acute myeloid leukemia, version 2.2013.

Margaret R O'Donnell1, Martin S Tallman, Camille N Abboud

  • 1From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 5Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 6Stanford Cancer Institute; 7Massachusetts General Hospital Cancer Center; 8University of Alabama at Birmingham Comprehensive Cancer Center; 9UCSF Helen Diller Family Comprehensive Cancer Center; 10Moffitt Cancer Center; 11UNMC Eppley Cancer Center at The Nebraska Medical Center; 12The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 13St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 14Fox Chase Cancer Center; 15Duke Cancer Institute; 16The University of Texas MD Anderson Cancer Center; 17Huntsman Cancer Institute at the University of Utah; 18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 19Dana-Farber Cancer Institute; 20Vanderbilt-Ingram Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.

Journal of the National Comprehensive Cancer Network : JNCCN
|September 14, 2013
PubMed
Summary
This summary is machine-generated.

NCCN updates provide new treatment options for acute promyelocytic leukemia (APL). New recommendations cover induction, consolidation, and maintenance regimens for low- and intermediate-risk APL patients.

More Related Videos

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Related Experiment Videos

Last Updated: May 7, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Area of Science:

  • Hematology
  • Oncology
  • Clinical Guidelines

Background:

  • Acute Myeloid Leukemia (AML) is a complex hematologic malignancy.
  • Acute promyelocytic leukemia (APL) is a distinct subtype of AML requiring specific management.
  • NCCN Guidelines offer evidence-based recommendations for cancer care.

Purpose of the Study:

  • To summarize recent updates to the NCCN Guidelines for Acute Myeloid Leukemia.
  • To highlight changes specifically within the acute promyelocytic leukemia (APL) section.
  • To discuss the clinical evidence supporting revised APL treatment recommendations.

Main Methods:

  • Review of NCCN Guidelines for Acute Myeloid Leukemia.
  • Analysis of updated recommendations for APL treatment.
  • Synthesis of clinical evidence supporting guideline changes.

Main Results:

  • New recommendations for induction and consolidation regimens in low- and intermediate-risk APL.
  • Updated guidance on maintenance strategies for APL patients.
  • Focus on evidence-based advancements in APL therapy.

Conclusions:

  • The updated NCCN Guidelines offer refined treatment approaches for APL.
  • These insights aim to improve clinical decision-making for APL management.
  • Evidence supports enhanced induction, consolidation, and maintenance strategies for APL.